New Stock News | Imne Bio Plans Hong Kong IPO Material Accepted by the China Securities Regulatory Commission

On September 6th, the China Securities Regulatory Commission (CSRC) issued the "Domestic Enterprises Overseas Issuance and Listing Filing Table (Initial Public Offering and Full Circulation) (as of September 5, 2024)". This week (September 2nd to 6th), Ying En Bio intends to list on the Hong Kong Stock Exchange and has had its materials accepted by the CSRC. According to the disclosure by the Hong Kong Stock Exchange on August 26th, Ying En Bio (Duality Biotherapeutics, Inc.) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley, Jefferies, and CITIC Securities as joint sponsors. Ying En Bio's filing type is an indirect overseas listing, with the acceptance date of the filing being September 4th, and Shanghai Chengming Zhenglu Law Firm serving as its domestic lawyer. According to the prospectus, Ying En Bio is a global leader in the field of Antibody-Drug Conjugates (ADCs), dedicated to developing a new generation of innovative ADC drugs for patients with cancer and autoimmune diseases. The company has established a variety of differentiated pipelines using its own ADC technology platform. The company is advancing these pipelines with the goal of revolutionizing cancer treatment modalities and providing therapies that can significantly improve global patient outcomes. Ying En Bio has stated that since its establishment in 2019, the company has built a highly innovative and differentiated pipeline consisting of 12 independently developed ADC candidate drugs, including six clinical-stage ADCs with potential in indications with significant unmet clinical needs, each of which is considered among the global leaders in terms of overall or key indication development progress according to Frost & Sullivan. In addition, two next-generation bispecific ADCs (BsADCs) and one ADC for the treatment of autoimmune diseases (Autoimmune ADC) are expected to enter the clinical stage between 2024 and 2026, along with several other preclinical ADCs.